genes per cell. 139
First, we verified that the lymph node-derived single cell suspensions were representative for 140 the cellular composition (B and T cells) of the lymphoma and its microenvironment in vivo. 141
We used sections of paraffin-embedded samples of the same lymph nodes, which were formalin 142 fixed directly after surgical excision and therefore represent the in vivo cellular composition, 143 and quantified B and T cell frequencies by immunohistochemistry (IHC, Supplementary Figure  144 1A). In parallel, we calculated B and T cell frequencies by flow cytometry and scRNA-seq in 145 single cell suspensions ( Supplementary Figure 1A, B ). The frequencies of B and T cells derived 146 from scRNA-seq correlated very well with the frequencies determined by flow cytometry 147 (r = 0.97, n = 12, Figure 1B ) and IHC (r = 0.92, n = 7, Figure 1C ). 148
Next, we aimed to distinguish malignant from non-malignant B cells and delineate these 149 populations in our single cell experiments. We took advantage of the fact that malignant B cell 150 populations express only one type of immunoglobulin light chain (LC), either κ or λ [22] . We 151 calculated the LC-ratio (κ/λ) based on RNA expression of the genes IGKC (coding for the 152 constant part of the κ LC) and IGLC2 (λ LC) for each single B cell and color-coded this ratio 153 8 in a t-distributed stochastic neighbor embedding (t-SNE) plot ( Figure 1D , E). In the malignant 154 lymph nodes, we could either identify both a non-malignant and malignant or only malignant 155 B cell clusters ( Supplementary Figure 2) . In contrast, reactive lymph node samples contained 156 only non-malignant B cells (see method section for details). 157
We further evaluated the frequencies of these subsets in a larger cohort of 41 lymph node 158 samples by flow cytometry, including those samples used for scRNA-seq. Both approaches 159 showed very similar frequencies of these cell subsets (r = 0.97, n = 12, 160 Supplementary Figure 3A genetic immune escape strategies that can be targeted using current therapeutic strategies [24] , 172 including checkpoint inhibitors [25] and bispecific antibodies [26] . Notably, lymphoma cells 173 can also orchestrate their tumor microenvironment so that certain T cell subsets support the 174 growth and proliferation of the tumor cells [27] . Even though these subsets have been 175 extensively studied by immunophenotyping, their transcriptional heterogeneity in B-NHL 176 lymph nodes, in particular at the single cell level, still remains to be elucidated. 177
We combined single cell RNA expression profiles of T cells from all 12 donors and jointly 178 visualized them by Uniform Manifold Approximation and Projection (UMAP), a dimension 179 reduction algorithm alternative to t-SNE [28] . Many well-established surface markers, which 180 are used to distinguish T cell subsets in flow cytometry studies, are insufficiently expressed on 181 the scRNA-seq level. We therefore chose unsupervised clustering to partition T cells into 182 transcriptionally distinct subsets, which were then annotated by differentially expressed marker 183 genes. All T cells from either reactive or malignant lymph nodes distributed to only four major 184 T cell subpopulations (Figure 2 A, B ). Note, that clusters were not driven by patients or disease 185 entity, suggesting only limited transcriptional heterogeneity across all donors. Apart from 186 conventional T helper cells (TH; CD4, IL7R, PLAC8, KLF2) and regulatory T cells (TREG; CD4, 187 9 IL2RA, FOXP3, ICOS), we identified a third T helper cell population, which was characterized 188 by overexpression of PDCD1 (PD1), ICOS, CXCR5, TOX, TOX2 and CD200 ( Figure 2C , 189 Supplementary Table 2 ), suggesting a T follicular helper cell (TFH) phenotype [29] [30] [31] [32] [33] . In 190 contrast to the diversity of T helper cells, we observed only one major cluster of cytotoxic T 191 cells (TTOX, GZMK, CCL4/5, GZMA, NKG7, CD8A) . However, the frequencies of the four 192 identified T cell subsets were highly variable between different B-NHL donors ( Figure 2D ) . 193 To study this variation in a larger cohort, we quantified the abovementioned T cell populations 194 in 39 lymph node samples of DLBCL, FL, mantle cell lymphoma and chronic lymphocytic 195 leukemia by flow cytometry using the most distinctive markers (CD3, CD4, CD8, CD25, 196 FoxP3, ICOS, PD1), as seen in Figure 2C . The frequencies of all T cell subsets derived from 197 scRNA-seq correlated well with the frequencies determined by flow cytometry (r = 0.69, 198 n = 10, Figure 2E ). We found that TFH cells were significantly increased in FL (two-sided 199 Wilcoxon test: p = 0.006, Figure 2F ), and TREG cell frequencies were significantly increased in 200 malignant lymph nodes, compared to the reactive ones (two-sided Wilcoxon test: p values as 201 indicated, Figure 2F ). 202
Taken together, we demonstrated that T cells derived from malignant B-NHL lymph nodes are 203 transcriptionally similar to those derived from non-malignant reactive lymph nodes. In contrast, 204 the proportion of individual T cell subsets differed significantly between lymphoma entities and 205 individual patients. This finding indicates that B-NHL shape their microenvironment by 206 influencing the recruitment of certain T cell subpopulations, but have less effect on their 207 transcriptional programs. Therefore, studying the frequencies of lymphoma infiltrating T cell 208 subsets and their effect on the outcome after immunotherapies might be highly relevant for the 209 development of biomarkers. 210 211
Identification of gene expression signatures driving B cell heterogeneity by scRNA-seq 212
Next, we examined the heterogeneity of the malignant and non-malignant B cells. To gain a 213 global overview of the gene expression pattern across all malignant and non-malignant B cells 214 from the 12 different donors, we combined their single cell RNA expression profiles, clustered 215 them jointly and visualized them by UMAP ( Figure 3A, B) . 216
Clustering partitioned the non-malignant B cells into two distinct subpopulations (C0-C1, 217 Figure 3A ). Among multiple differentially expressed genes between these two subsets 218
( Supplementary Table 3 ), we found IGHM and CD72 to be overexpressed in cluster C0, which 219 characterizes naïve B cells [34] , and CD27 and IGHG1 to be overexpressed in cluster C1, which 220 characterizes memory B cells [35] . 221 10 Of the eight transcriptionally distinct clusters formed by the malignant B cells (C2-C9, Figure  222 3A), six exclusively contained cells of only one donor ( Figure 3A, B ). This suggests a higher 223 degree of inter-patient heterogeneity for malignant than for non-malignant B cells. We 224 performed a gene set enrichment analysis (GSEA) on the mean expression differences between 225 each malignant B cell cluster and all non-malignant cells, which revealed multiple cluster-226 specific gene sets ( Figure 3C ). Germinal center (GC)-associated gene expression signatures 227 were significantly enriched in all clusters except for cluster 6, which exclusively contained 228 malignant B cells of DLBCL3. This finding supports the classification of all B-NHL cells as 229 either GCB type DLBCL or FL, except for the remaining DLBCL3 sample, which was 230 classified as a non-GCB type DLBCL based on the Hans-classifier (Supplementary 231 Table 1 ) [36] . Individual clusters were characterized by oncogenic transcriptional programs, 232 which indicated activation of oncogenic MYC or STK33 signaling ( Figure 3D ). 233
Inter-patient heterogeneity of B cell lymphomas also comprises their proliferative capacity, 234 which can vary from very low in FL to very high in DLBCL. We determined the proportion of 235 B cells in S, G2 or M phase based on their single cell RNA profile (Supplementary Figure 4A ) 236 and observed a high correlation with flow cytometry-and IHC-based staining of Ki67 (R = 0.83 237 scRNA-seq to flow cytometry, R = 0.92, scRNA-seq to IHC, Supplementary Figure 4B ). 238
In summary, these results indicate that inter-patient heterogeneity of malignant B cells, 239
including their diverse proliferative activity, can be captured by the scRNA-Seq and can be 240 linked to lymphoma-specific transcription signatures. Non-malignant B cells, however, had 241 similar transcriptional profiles across different donors. 242
243

Decoding the crosstalk between T cells and malignant B cells in the lymph node 244 microenvironment 245
Above, we concluded that B cell lymphomas shape their microenvironment by modulating the 246 frequency of different subsets of lymphoma infiltrating T cells. We now aimed to understand 247 through which potential ligand-receptor interactions malignant B cells could benefit from their 248 specific T cell microenvironment. For this purpose, we adopted a computational approach 249 described by and analyzed 760 known ligand-receptor combinations 250
( Supplementary Table 4 ) to identify the most significant interactions between malignant B cells 251 and lymphoma infiltrating T cells within the lymph node microenvironment ( Figure 4A ). 252
This analysis suggested that malignant B cells could receive costimulatory and coinhibitory 253 signals by all four major T cell subsets, via CD80/CD86-CD28 and CD80/CD86-CTLA, while 254 interactions via BCMA-BAFF, BAFF-R-BAFF and CD40-CD40LG could predominantly be 255 11 mediated by TH or TREG cells. Significant interaction scores of IL4-IL4R and IL4-IL13RA1  256 were exclusively observed between TFH and malignant B cells, providing further evidence that 257 TFH cells represent the most important source of IL4 production in B cell lymphoma [38] . This 258 observation might be of clinical relevance because the IL4/IL4R interaction is discussed as 259 potential resistance mechanism against Bruton's tyrosine kinase (BTK) inhibitors [39, 40] . In 260 line with the current state of knowledge [41] [42] [43] , we also observed strong interaction scores for 261 TFH via IL21-IL21R with malignant B cells and via IL2-IL2R with other T cell subsets. This 262 analysis supports the classification of TFH cell as one of the four main T cell subsets within the 263 lymph node microenvironment and reveals that each subset may provide a distinct panel of 264 stimuli to interact with malignant B cells. 265
266
Dissecting transcriptional intratumor heterogeneity using multicolor flow cytometry 267
Intratumor heterogeneity of nodal B cell lymphoma is a well-known phenomenon, however, 268 most available studies infer intratumor heterogeneity from variant allele frequencies of genetic 269 alterations corrected for purity, ploidy and multiplicity of local copy number [44, 45] . 270
Here, we aimed to investigate the genomic, transcriptomic and functional (drug response) layers 271 of intratumor heterogeneity from single cells. Unsupervised clustering of scRNA-seq profiles 272 of malignant and non-malignant B cells revealed that all malignant samples were composed of 273 at least two or more transcriptionally distinct subclusters (Supplementary Figure 5 ). We aimed 274 to validate scRNA-based clusters at the cellular level to understand if this clustering represents 275 biologically and clinically relevant differences. Therefore, we selected three samples (FL4, 276 tFL1, DLBCL1) based on the availability of material for follow-up studies. We inferred 277 differentially expressed surface markers from single cell expression profiles and first validated 278 the distinction of scRNA-based clusters by flow cytometry. In a second step, we cultured lymph 279 node derived lymphocytes with 58 different drugs in 5 concentrations ( Supplementary Table 5 ) 280 and stained them with specific antibody combinations to assess their drug response profiles by 281 flow cytometry. In a third step, we sorted subpopulation and performed genome sequencing for 282 each subclone (tFL1, DLBCL1). 283
284
Verifying five transcriptionally distinct clusters in follicular lymphoma sample 285
The FL4 sample was collected at initial diagnosis. Based on single cell gene expression 286 profiling, we identified five different B cell subpopulations (Supplementary Figure 6A ). We 287 aimed to validate all five clusters (C1 to C5) at the cellular level by flow cytometry and hence, 288 we stained the differentially expressed surface markers CD44, CD24, CD22, CD27, kappa and 289 12 lambda light chain (encoded by IGKC and IGLC2, Supplementary Figure 6B ). Using the ratio 290 of IGKC and IGLC2 (see Methods for details), we found benign B cells in C1, lambda-restricted 291 malignant B cells in C2, and malignant B cells with only marginal expression of IGKC and 292 IGLC2 in C3 to C5 (Supplementary Figure 6C ). The pattern of light chain expression could be 293 perfectly comprehended using flow cytometry (Supplementary Figure 6D ), enabling us to 294 differentiate C1 versus C2 versus C3, C4 and C5. Cluster C3 could then be recognized by a 295 high expression of CD44 ( Supplementary Figure 6D , 6E). To further distinguish C4 and C5 296 among the CD44 Low cells, we combined CD22, CD27 and CD24 and detected a subpopulation 297 with CD22 High , CD27 High and CD24 Low , which corresponded to the expression pattern of cluster 298 C5 (Supplementary Figure 6F ). This approach allowed us to proof all five scRNA-based 299 clusters by flow cytometry with comparable frequencies. 300
To assess subclone-specific drug response, we stained for kappa and lambda light chains and 301 focused on the two major populations (C2 ≙ lambda + , C3-C5 ≙ kappa/lambda -). We did not 302 observe differential responses for the majority of targeted drugs, but we found that only the 303 kappa/lambdacluster was sensitive to chemotherapeutics (Supplementary Figure 6G Figure 7A) , 314 with no cells in G2 or M phase (Supplementary Figure 7B ). This suggests that this cluster 315 represents a proliferating, thus aggressive component of the transformed FL. We performed a 316 GSEA on the mean expression differences between the two malignant clusters, which revealed 317 that gene expression signatures associated with MYC, MTORC1, and the G2M transition [46] 318 were significantly enriched in the presumptively aggressive malignant B cell subclone 319 (Supplementary Figure 7D -F). 320
Among the genes differentially expressed between both subclones, we found FCGR2B ( Figure  321 5A), which encodes a surface receptor protein (CD32B), to be exclusively expressed in the 322 presumptively indolent subclone. Thus, we confirmed the existence of three B cell populations 323 13 by flow cytometry ( Figure 5C , see Supplementary Figure 8A for complete gating strategy). 324 CD10 was strongly positive in both malignant B cell populations (CD32 High , CD32 Low ), but not 325 in non-malignant B cells. 326
As described above, we measured the ex vivo drug responses separately for each subclone 327 ( Figure 5D , E) and observed very different drug response profiles for the two malignant 328 subclones. The BTK inhibitors, ibrutinib, acalabrutinib, and tirabrutinib, and the 329 immunomodulatory imide drugs (pomalidomide, lenalidomide), were exclusively active in the 330 CD32 Low subclone, whereas HDAC inhibitors (panobinostat, romidepsin, vorinostat) were 331 more active in the CD32 High subclone. 332
Based on CD32 and CD10 expression, we sorted the three B cell subclones by flow cytometry 333 (Supplementary Figure 8A Figure 7F ). Only the CD32 Low subclone harbored a trisomy 12 ( Figure 5F ), which was 338 confirmed by scRNA-seq data ( Figure 5G ). Trisomy 12 has been associated with a better 339 response to B cell receptor (BCR) signaling inhibitors [47] , which was consistent with our 340 observation that this subclone was more responsive to these drugs ( Figure 5D , E). We also 341 detected 157 somatic single nucleotide variants (SNV) in exonic regions, of which 25 (15.9 %) 342 or 24 (15. 2%) were exclusively detected in the CD32 High or CD32 Low subclone, respectively 343 ( Figure 5H , I, Supplementary Table 6 ). However, the majority of somatic SNVs were equally 344 represented in both subclones, indicating a phylogenetic relationship. We compared the allele 345 count of all exonic SNVs between all three B cell populations and did not detect somatic SNV 346 in healthy B cells ( Figure 5J ), which supports the validity of our sorting approach. 347
Taken together, scRNA-seq allowed us to identify different subclones within the same lymph 348 node, which were genetically and functionally distinct in clinically-relevant aspects. 349
350
A subclone-specific copy number variation of MYC drives a distinct gene expression and 351 drug response program 352
The DLBCL1 sample was collected from a patient with a chemotherapy refractory disease 353 during progression, but before retreatment. Using scRNA-seq, we identified two distinct 354 clusters of malignant B cells, which exhibited a high number of differentially expressed genes 355 associated with diverse cellular programs ( Figure 6A , B), such as BCR signaling (PRKCB, 356 NFKB1I) , cytokine signaling (LGALS9, IFITM1), MAPK signaling (RGS13, FBLN5) and 357 14 antigen processing (PTPN22, SELL, CD48). Among the differentially expressed genes, we 358 found CD48 and SELL (Supplementary Figure 9A, B) , which encode for the surface markers 359 CD48 and CD62L respectively. Staining for CD48 and CD62L by flow cytometry validated the 360 existence of the two distinct subclones ( Figure 6C ). The proportions of both clusters 361 (CD48 High CD62L + , CD48 Low CD62L -) calculated based on flow cytometry and scRNA-seq were 362 comparable, indicating good concordance between RNA and protein expression. We measured 363 again the ex vivo drug responses for each subclone (Figure 6D In total, we detected 240 non-synonymous SNV located in exonic regions (Supplementary  373   Table 7) , however, only 1 (0.4 %) or 5 (2.1 %) SNV were exclusively detected in the 374 CD48 Low CD62Lor the CD48 High CD62L + cluster, respectively ( Figure 6F ). We further 375 compared CNV profiles of the two subclones and detected a number of differences: the 376 CD48 High CD62L + cluster carried an additional copy of MYC (8q24, Figure 6G ), which was 377 reflected by increased MYC expression levels (Supplementary Figure 9C ). The q arm of 378 chromosome 14 harbored two copy number gains and one copy number loss in the 379 CD48 High CD62L + cluster ( Figure 6G ). Moreover, chromosome X exhibited a copy number gain 380 of the p arm in the CD48 High CD62L + cluster, and a copy number loss of the q arm in the 381 CD48 Low CD62Lcluster ( Figure 6G ). 382
Since pathologic activation of MYC renders cells sensitive to BET inhibitors [48, 49] , we 383 performed intracellular flow cytometry-based staining of MYC at baseline and after 24 hours 384 incubation with and without the two BET inhibitors, I-BET-762 or OTX015. We confirmed the 385 increased MYC expression level of the CD48 High CD62L + subclone at baseline ( Figure 6H 
In vivo retreatment confirms ex vivo prediction of subpopulation-specific drug response 391
To exemplify the translational relevance of subclone-specific drug responses, we performed 392 WES of DLBCL1 during the second relapse after retreatment with high-dose cytarabine. Based 393 on ex vivo drug perturbation we had predicted that the CD48 High CD62L + but not the 394 CD48 Low CD62Lsubpopulation would respond to cytarabine ( Figure 6D ). We compared 395 several synonymous SNV exclusive to the CD48 High CD62L + subpopulation before retreatment 396 and during second relapse, and observed that the cytarabine-sensitive subpopulation was 397 successfully eradicated ( Figure 6I ). Due to the lack of sufficiently exclusive SNV in the 398 resistant subclone, we took advantage of the loss of heterozygosity (LOH) on chromosome Xq 399 ( Figure 6G ) to determine the aberrant fraction of cells harboring a loss of Xq before and after 400 retreatment. We found that the fraction of chemotherapy-resistant cells, harboring the loss of 401
Xq, increased from 72 % to 93 % (see methods section for details). 402
In summary, we dissected the intratumor heterogeneity of the DLBCL1 sample on the 403 transcriptional, genomic, and drug response level. This clinically relevant example highlights 404 the huge translational relevance of tumor subpopulations and their specific drug response 405 profile for personalized cancer treatment. 406 16 Discussion 407
Intratumor heterogeneity poses a significant challenge for the clinical management of cancer 408 patients. Advances of single cell technologies facilitated the profiling of intratumor 409 heterogeneity at an unprecedented resolution [50] . Most of these studies comprehensively 410 describe intratumor heterogeneity on the transcriptional level, but do not explore its functional 411 consequences such as response or resistance to drugs. In this study, we address this limitation 412 and identify transcriptionally distinct malignant subclones in B-NHL lymph node biopsies. We 413 study differential drug response patterns of these subclones and genetic events which likely 414 drove these differences. 415
Our analysis revealed the coexistence of up to four transcriptionally distinct subpopulations of 416 malignant cells within individual B-NHL lymph node samples. This result recapitulates similar 417 observations in follicular lymphoma [45] , multiple myeloma [51] and other cancer entities [8, 418 12, 52] . We and others attributed this heterogeneity to differentially enriched gene sets, which 419 indicate, for instance, activity of MYC, proliferation, or germinal center experience. However, 420
we went further and established a straightforward strategy to prove the coexistence of up to four 421 different tumor subpopulations at the cellular level. We subsequently performed perturbation 422 assays with a comprehensive panel of clinically relevant drugs and observed that tumor 423 subclones within the same lymph node responded strikingly different both to targeted 424 compounds, such as ibrutinib, but also chemotherapeutics. The study by de Boer and colleagues 425 supports our observation by demonstrating that acute myeloid leukemia subclones, which were 426 identified on the basis of 50 leukemia-enriched plasma membrane proteins, had distinct 427 functional properties including a differential sensitivity to FLT3-inhibition driven by a 428 subclonal FLT3-ITD mutation [53] . Most preclinical in vitro and in vivo drug screens do not 429 address such clonal heterogeneity, which may explain the failure of numerous drug candidates 430 in the clinic [47] . For a single patient, we even demonstrated that the ex vivo drug response 431 profiling correctly predicted the treatment sensitivity of tumor subclones in vivo. The 432 prospective identification of rational combinations of cancer drugs that effectively target co-433 existing tumor subclones separately could avoid the outgrowth of resistant tumor clones under 434 therapeutic pressure of a single drug, and would thereby improve efficacy of cancer treatments. 435
Our study addresses this limitation of many ex vivo drug perturbation studies, and, due to its 436 unbiased approach to prospectively dissect the malignant substructure, it is also generalizable 437 to other cancer entities. However, due to the limitation of lymph node derived primary cells, 438
we have to acknowledge that we could not apply our approach to all samples. Further studies 439 17 are necessary to expand this approach and to address also spatial heterogeneity of malignant 440 tumors. 441
Our approach enabled us to directly identify genetic factors that underlie the transcriptional and 442 drug response differences between subclones. This distinguishes our work from a previous 443 scRNA-seq study in FL, which indirectly compared allele frequencies of bulk WES with the 444 size of transcriptionally distinct subclones [45] . The authors found a correlation between 445 genomic alterations and subclonal fractions and concluded that somatic mutations are 446 associated with transcriptional differences. These findings are in contrast to another study, 447 which correlated subclusters derived from targeted single cell expression profiling of 91 genes 448 with subclusters derived from single cell immunoglobulin heavy-chain (IGH) sequencing. In 449 this study, the authors concluded that distinct gene expression clusters were not associated with 450 subclones derived from IGH hypermutations [54] . While these studies provide only indirect 451 evidence, we physically sorted tumor subclones and normal B cells, and performed WGS or 452 WES separately for transcriptionally distinct lymphoma subpopulations. With regard to somatic 453 mutations, we observed two different scenarios: in the DLBCL1 sample we identified almost 454 no somatic SNVs to be exclusive for one or the other subclone, whereas in the tFL1 sample we 455 found up to 15% exclusive somatic SNVs in each subclone. However, both examples represent 456 scenarios where subclone specific drug profiles could not have been predicted by means of gene 457 mutation sequencing. We further compared CNV profiles of the same tumor subclones, and 458 found that all subclones harbored significantly different CNV profiles, suggesting that copy 459 number alterations represent an important layer of genetic events which can drive differential 460 gene expression programs and drug response profiles. Although our results support the general 461 notion that genetic events drive subclone specific differences in drug response, they also 462 highlight the difficulty to predict drug responses based on only genome sequencing in clinical 463 practice. It might therefore be beneficial to obtain both genetic-and drug response profiles for 464 personalized treatment decisions. 465
Exploring the heterogeneity of the immune microenvironment in B-NHL has the potential to 466 better reveal how lymphomas shape their microenvironment and how lymphoma patients could 467 be better stratified for the treatment with immunotherapies. T cells represented the largest non-468 malignant population in B NHL lymph node biopsies. We identified four major, 469 transcriptionally distinct T cell subpopulations, which were annotated as cytotoxic T cells, 470 regulatory T helper cells, conventional T helper cells and T follicular helper cells [29] [30] [31] [32] [33] . We 471 measured the frequency of these T cell subsets in an extended cohort of malignant lymph node 472 biopsies and found T follicular helper cells to be enriched in FL, which is in line with previous 473 18 flow cytometry-based studies [33, 55] . These T cell subsets displayed only limited 474 transcriptional heterogeneity with less variability between lymph nodes compared to malignant 475 cells. However, the frequencies of these T cell subsets varied significantly across donors, which 476 suggests that B-NHL shape their microenvironment by regulating the recruitment of different 477 T cell subsets. This observation might be of clinical relevance, because cold tumors with very 478 few infiltrating T cells have been reported to respond less well to immunotherapies [56] . 479
Despite the rather small number of analyzed B-NHL patients, our study is of high clinical 480
relevance. We demonstrated that the prospective identification of pre-existing transcriptionally 481 distinct malignant subclones might be of diagnostic value to detect difficult to treat tumor 482 subclones. In addition, our research establishes scRNA-seq as a new key technology for precise 483 molecular profiling of relapsed and refractory nodal B cell lymphomas, and facilitates the 484 design of new and molecularly-informed diagnosis and treatment strategies. 485 19
Online Methods 486
Patients samples and lymph node procession 487
Our study was approved by the Ethics Committee of the University of Heidelberg. Informed 488 consent was obtained in advance. Immediately after the excision, the lymph node was cut in 489 small pieces and put into Roswell Park Memorial Institute (Gibco) medium supplemented with 490 10 % fetal bovine serum (FBS, Gibco), penicillin and streptomycin (Gibco) at a final 491 concentration of 100 U/ml and 100 µg/ml and L-Glutamine (Gibco) at a final concentration of 492 2 mM. After filtering by a 40 µm strainer, cells were washed once with phosphate-buffered 493 saline (PBS, Gibco and put into RPMI medium (Gibco) medium supplemented with 20 % FBS 494 (Gibco) and 10 % dimethyl sulfoxide (DMSO, Serva), and then cryopreserved in liquid nitrogen 495 until further analysis. an 496 497
Quantification of immunohistochemical staining 498
Formalin fixed lymph node tissue were processed through the hospital's routine 499 immunohistochemistry pipeline and thereby stained for CD3, PAX5 and Ki67 (all Ventana). 500
After completion of diagnostics, the corresponding slides were scanned for a subset of patients 501 (n = 7). To quantify the frequencies of B and T cells, the open source software QuPath (v0.1.2) 502 was used for PAX5 or CD3 stained slides according to the recommended workflow [57] . After 503 detection of about 100.000 cells per slide, the measurements were exported and further analyzed 504 using R. We visualized the intracellular signal of diaminobenzidine staining of all detected 505 events in a histogram. For the staining of PAX5 and CD3 we observed two clear peaks for all 506 samples and set a threshold in between. Cells with an intracellular signal of CD3 or PAX5 507 greater than this threshold were regarded as T cells or B cells, respectively. The proportion of 508 Ki67 + cells was obtained from routine pathology reports. 509 510 Surface and intracellular staining by flow cytometry 511
As described above, lymph node derived cells were thawed and stained for viability using a 512 fixable viability dye e506 (Thermo Fisher Scientific) and for different surface markers 513 depending on the experimental setup. The following surface antibodies were used: anti-CD3- a high throughput sampler (HTS) system (BD Biosciences). Approximately 5,000 to 10,000 563 events were recorded per well. Flow cytometry data was analyzed using FlowJo software (Tree 564 Star). The gating strategy is illustrated in Supplementary Figure 8 . We ruled out that significant 565 up-or downregulation of subclone-discriminating surface antigens confound subclone-specific 566 drug response assessment by evaluating the fluorescence intensity of corresponding markers 567 before and after drug treatment ( Supplementary Figure 10) . 568 569
Fluorescence-activated cell sorting of B cell subclones 570
Lymph node cells were stained as described above. Sorting was performed at a FACS Aria 571 Fusion (BD Biosciences). We sorted either for e506 -CD3 -CD19 + CD48 -CD62Land e506 -572 CD3 -CD19 + CD48 -CD62L -(DLBCL1) or for e506 -CD3 -CD19 + CD10 -, e506 -CD3 -CD19 + 573 CD10 + kappa + , CD32 low and e506 -CD3 -CD19 + CD10 + kappa + , CD32 high cells (tFL). The gating 574 strategy is illustrated in Supplementary Figure 8 . All relevant fractions were analyzed post-575 sorting to confirm a purity of at least 95 %. 576
577
Whole genome and whole exome sequencing 578 DNA was extracted using the DNeasy mini kit (Qiagen) according to the manufacturers 579 protocol, followed by quality control using gel electrophoresis and a TapeStation 2200 system 580 (Agilent). Samples were prepared either for WGS or WES, as previously described [60] . Exome 581 capturing was performed using SureSelect Human All Exon V5 in-solution capture reagents 582 (Agilent). If samples were destined for WES on an Illumina HiSeq 2500 instrument, then 1.5 583 µg genomic DNA were fragmented to 150 to 200 bp insert size with a Covaris S2 device, and 584 250 ng of Illumina adapter-containing libraries were hybridized with exome baits at 65°C for 585 22 16 hours. If samples were destined for WES on an Illumina HiSeq 4000 instrument, then 200 586 ng genomic DNA were fragmented to 300 bp insert size with a Covaris LE220 or E220 device, 587 and 750 ng of adapter-containing libraries were hybridized with exome baits at 65°C for 16 588 hours. If samples were destined for WGS on an Illumina HiSeq X instrument, then 100 ng of 589 genomic DNA were fragmented to 450 bp insert size with a Covaris LE220 or E220 device, 590 and libraries were prepared using the TruSeq Nano Kit (Illumina). On all platforms paired-end 591 sequencing was carried out according to the manufacturer's recommendations, yielding read 592 lengths of 101 bp (4000) or 151 bp (HiSeq X). 593
594
Single cell RNA sequencing data processing 595
The Cell Ranger analysis pipeline (v2.1, 10x Genomics) was used to demultiplex the raw base 596 call files and to convert them into FASTQ files. FASTQ files were aligned to the reference 597 genome (hg38) and filtered. Final numbers of cell barcodes, unique molecular identifiers (UMI) 598 per cell, median genes and sequencing saturation are summarized in Supplementary Table 8 . 599
600
Filtering and normalizing single cell RNA sequencing data 601
The R package Seurat [61] (v2.3.3) was used to perform quality control and normalization. 602
Gene count per cell, UMI count per cell and the percentage of mitochondrial and ribosomal 603 transcripts were computed using the functions of the Seurat package. Genes expressed in three 604 cells or fewer were excluded from downstream analysis. Libraries with a percentage of 605 mitochondrial transcripts greater than 5%, along with those with less than 200 genes were 606 filtered out prior to further analysis. Since aggressive lymphomas displayed higher gene and 607 UMI count, the upper limit was set with regard to each sample. Counts were adjusted for cell-608 specific sampling ("normalized") using the LogNormalize function with the default scale factor 609 of 10,000. 610
611
Assessing the cell cycle state using scRNA-seq data 612
The cell cycle state was assessed using the gene set and scoring system, described by Tirosh 613 and colleagues [8] . Briefly, the S-Score and the G2M-Score were calculated based on a list of 614 43 S phase-specific and 54 G2 or M phase-specific genes. The calculation of the actual scores 615 was performed using the CellCycleScoring function of the Seurat R package. 616 617 23
Analysis of ligand-receptor interactions in scRNA-Seq data 618
We used the CellPhoneDB database [37] as basis for potential cell-cell interactions, but 619 expanded the list by important B to T cell interactions ( Supplementary Table 4 ). To assess the 620 significance of each interaction, we adapted a statistical framework recently described by 621
Vento-Tormo and colleagues [37] to our purpose. Importantly, we considered only genes which 622 were expressed in 5 % of at least one cell type. 623
Briefly, we performed pairwise comparisons between the different T and B cell subtypes for 624 each ligand-receptor pair and sample. For each combination of two different cell types and each 625 ligand-receptor-pair, we permuted the cluster labels of cells at least 1,000 times and determined 626 the mean interaction score (mean expression of ligand in cell type A times mean expression of 627 receptor in cell type B). A p value was determined by calculating the proportion of permuted 628 interaction scores which were by hazard higher than the actual interaction score. All interactions 629 were calculated sample-wise. To determine which interactions were most relevant across 630 different samples, we calculated the mean interaction scores and combined the different p 631 values using the Fisher's method. Then, p values were corrected using the Benjamini-Hochberg 632 method. The R code is available on our GitHub repository (see code availability statement 633 below). were applied to all samples. UMAP was used instead of t-SNE for combined data sets because 648 it is significantly faster than t-SNE and better preserves aspects of global structure in larger data 649 sets [28] . Differentially expressed genes between the clusters were identified using the 650 to determine a confidence score for each variant by a heuristic punishment scheme and only 675 high confidence variants were kept for further analysis. In addition, variants with strong read 676 biases according to the strand bias filter were removed. 677
Genomic structural rearrangements (SVs) were identified using the SOPHIA algorithm 678 (unpublished, source code available at https://bitbucket.org/utoprak/sophia/). Briefly, 679 supplementary alignments as produced by bwa-mem are used as indicators of potential 680 underlying SVs. Candidates are filtered by comparing them to a background control set of 681 sequencing data obtained using normal blood samples from a background population database 682 of 3261 patients from published TCGA and ICGC studies as well as published and unpublished 683 studies of the German Cancer Research Center (DKFZ). 684 25 Allele-specific CNV were detected using ACEseq (allele-specific copy number estimation from 685 WGS) [69] for WGS data and CNVkit for WES data [70] . ACEseq determines absolute allele-686 specific copy numbers as well as tumor ploidy and tumor cell content based on coverage ratios 687 of tumor and control as well as the B-allele frequency (BAF) of heterozygous single-nucleotide 688 polymorphisms (SNPs). SVs called by SOPHIA were incorporated to improve genome 689 segmentation. 690 691
Multi tumor comparison 692
To compare multi tumor samples of the same donor, every SNV position in each sample was 693 determined using samtools mpileup 1.6. At each of these SNV positions, the variant allele 694 fraction was determined by calculating the ratio between the number of variant reads and the 695 total coverage at that position. To correct the variant allele fraction for actual tumor cell content, 696 a scaling factor was incorporated, comprising ploidy and total copy number (TCN) estimates 697 obtained from ACEseq/CNVkit. Specifically, the scaling factor is obtained as the ratio between 698 purity corrected number of alleles in the tumor (TCN_tumor purity_tumor) and purity corrected 699 total number of alleles in the sample ((TCN_tumor * purity_tumor) + 2 * (1 -purity_tumor)). The raw single cell count tables can be downloaded here doi.org/10.11588/data/VRJUNV. This 718 link will be activated upon publication and is accessible without further restriction. 719
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High-dose cytarabine treatment in vivo
